Literature DB >> 12647942

The burden of COPD in Italy: results from the Confronting COPD survey.

R Dal Negro1, A Rossi, I Cerveri.   

Abstract

Chronic obstructive pulmonary disease (COPD) is a disease state characterized by airflow limitation that is not fully reversible, and progressive lung function decline. In Italy, an estimated 2.6 million men and women have COPD, and the disease causes around 18 000 deaths each year. In addition to mortality, morbidity from COPD results in substantial use of secondary healthcare resources. The burden of COPD in Italy may be due to the underdiagnosis of the disease by healthcare professionals, particularly in the early stages of the disease, and a lack of awareness among physicians of recommended treatment practices. In an attempt to address the need for information on the burden of COPD, a large-scale international survey, Confronting COPD in North America and Europe, assessed clinical outcomes, use of healthcare resources and loss of productivity in the workplace, and the economic cost of this disease in Italy and six other countries. In Italy, the economic analysis of the survey data showed that the mean annual cost of COPD to the healthcare system was Euro 1261.25 per patient Indirect costs were estimated at Euro 47.29 per patient, bringing the societal cost of the disease to Euro 1308.54 per patient. Three-quarters of the direct per patient cost of COPD in Italy were accounted for by inpatient hospitalizations (Euro 963.10), suggesting that interventions aimed at preventing exacerbations could alleviate the burden of COPD in Italy. The high impact of COPD on the Italian healthcare system is also likely to be a consequence of the underdiagnosis and undertreatment of the disease, suggesting that costs may be reduced by increasing the utilization of spirometry as a diagnostic tool, and improving physician adherence to treatment guidelines. Patients with severe COPD and other comorbidities showed higher costs (Euro 6366 and Euro 1861, respectively) than patients with mild disease (Euro 441) or no comorbidities (Euro 1021), underlying the importance of smoking cessation interventions to prevent disease progression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12647942     DOI: 10.1016/s0954-6111(03)80024-0

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  19 in total

Review 1.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 2.  Systematic review of humanistic and economic burden of symptomatic chronic obstructive pulmonary disease.

Authors:  Kunal Srivastava; Deepika Thakur; Sheetal Sharma; Yogesh Suresh Punekar
Journal:  Pharmacoeconomics       Date:  2015-05       Impact factor: 4.981

3.  Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy.

Authors:  O Zaniolo; S Iannazzo; L Pradelli; M Miravitlles
Journal:  Eur J Health Econ       Date:  2010-11-18

4.  A Methodological Framework for the Integrated Design of Decision-Intensive Care Pathways-an Application to the Management of COPD Patients.

Authors:  Carlo Combi; Barbara Oliboni; Alessandro Zardini; Francesca Zerbato
Journal:  J Healthc Inform Res       Date:  2017-10-17

5.  Burden of COPD in a government health care system: a retrospective observational study using data from the US Veterans Affairs population.

Authors:  Amir Sharafkhaneh; Nancy J Petersen; Hong-Jen Yu; Anand A Dalal; Michael L Johnson; Nicola A Hanania
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-05-06

6.  How different combinations of comorbidities affect healthcare use by elderly patients with obstructive lung disease.

Authors:  Alessandra Buja; Andrea Bardin; Giulia Grotto; Stefania Elvini; Pietro Gallina; Giulia Zumerle; Patrizia Benini; Domenico Scibetta; Vincenzo Baldo
Journal:  NPJ Prim Care Respir Med       Date:  2021-05-25       Impact factor: 2.871

7.  Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and bronchodilators for severe and very severe COPD patients.

Authors:  Negro Roberto Dal; M Eandi; L Pradelli; S Iannazzo
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

Review 8.  New clinical insights into chronic obstructive pulmonary disease and their implications for pharmacoeconomic analyses.

Authors:  Douglas W Mapel; Melissa H Roberts
Journal:  Pharmacoeconomics       Date:  2012-10-01       Impact factor: 4.981

9.  COPD a social disease: inappropriateness and pharmaco-economics. The role of the specialist: present and future.

Authors:  Claudio F Donner; Mirco Lusuardi
Journal:  Multidiscip Respir Med       Date:  2010-12-20

Review 10.  Pharmacoeconomics in COPD: lessons for the future.

Authors:  Helen J Starkie; Andrew H Briggs; Mike G Chambers
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.